Provectus Biopharmaceuticals opens patient enrollment and begins phase 3 international FDA comparative clinical trial of PV-10 for melanoma

Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, enters phase 3 and has opened enrollment of patients for its phase 3 international FDA...